DLI after haploidentical BMT with post-transplant CY

Bone Marrow Transplantation

Volumn 50, Issue 1, 2015, Pages 56-61

  Ghiso, A ^a   Raiola, A M ^a   Gualandi, F ^a   Dominietto, A ^a   Varaldo, R ^a   Van Lint, M T ^a   Bregante, S ^a   Di Grazia, C ^a   Lamparelli, T ^a   Galaverna, F ^a   Stasia, A ^a   Luchetti, S ^a   Geroldi, S ^a   Grasso, R ^a   Colombo, N ^a   Bacigalupo, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BENDAMUSTINE; BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IDARUBICIN; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; THIOTEPA; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; APLASIA; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CD3+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; EXTRACORPOREAL PHOTOPHERESIS; FEMALE; GRAFT VERSUS HOST REACTION; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; INFECTIOUS COMPLICATION; LEUKEMIA; LEUKEMIA RELAPSE; MALE; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PUVA; SEPSIS; WHOLE BODY RADIATION; ADOLESCENT; ALLOGRAFT; GRAFT VS HOST DISEASE; LIVING DONOR; LYMPHOCYTE TRANSFUSION; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; SURVIVAL RATE; TIME;

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HODGKIN DISEASE; HUMANS; LEUKEMIA; LIVING DONORS; LYMPHOCYTE TRANSFUSION; MIDDLE AGED; RECURRENCE; SURVIVAL RATE; TIME FACTORS;

EID: 84920605828     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.217     Document Type: Article

References (24)

1. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
2. Bortin MM, Rimm AA, Saltzstein EC. Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia. Science 1973; 179: 811-813.
3. Tomblyn M, Lazarus HM. Donor lymphocyte infusions. The long and winding road: how should it be traveled? Bone Marrow Transplant 2008; 42: 569-579.
4. De Lima M, Bonamino M, Vasconcelos Z, Colares M, Diamond H, Zalcberg I et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft versus-host disease. Bone Marrow Transplant 2001; 27: 73B.
5. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
6. Bacigalupo A, Soracco M, Vassallo F, Abate M, Van Lint MT, Gualandi F et al. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 927-932.
7. Mackinnon S, Papadopoulos E, Carabasi M, Reich L, Collins N, Boulad F et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
8. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone marrow transplantation. N Engl J Med 1975; 292: 895-902.
9. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full-haplotype mismatched hematopoietic stem cell transplantation: a phase II study in patients with acute leukemia at high risk or relapse. J Clin Oncol 2005; 23: 3447-3454.
10. Kolb HJ, Günther W, Schumm M, Holler E, Wilmanns W, Thierfelder S. Adoptive immunotherapy in canine chimeras. Transplantation 1997; 63: 430-436.
11. Huang Xiao-Jun, Liu Dai-Hong, Liu Kai-Yan, Xu Lan-Ping, Chen Huan, Han Wei. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92: 414-417.
12. Yan C-H, Liu D-H, Xu L-P, Liu K-Y, Zhao T, Wang Y et al. Modified donor lymphocyte infusion associated acute graft-versus-host disease after haploidentical T-cell replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transplant 2012; 26: 868-876.
13. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F et al. Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning. Biol Blood Marrow Transplant 2013; 19: 117-122.
14. Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant 2013; 49: 190-194.
15. Pozzi S, Geroldi S, Tedone E, Luchetti S, Grasso R, Colombo N et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol 2013; 160: 503-509.
16. Bar M, Sandmaier BM, Inamoto Y, Bruno B, Hari P, Chauncey T et al. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant 2013; 19: 949-957.
17. Raiola AM, Van Lint MT, Valbonesi M, Lamparelli T, Gualandi F, Occhini D et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003; 31: 687-693.
18. Zeidan AM, Forde PM, Symons H, Chen A, Smith BD, Pratz K et al. HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant 2013; 20: 314-318.
19. Anderlini P, Acholonu SA, Okoroji GJ, Andersson BS, Couriel DR, De Lima MJ et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant 2004; 34: 511-514.
20. De Rosa G, Pezzullo L, Scarpato N, Selleri C, Lucania A, Rotoli B. Donor lymphocyte infusion for post-transplant relapse of Hodgkin's lymphoma. Haematologica 2000; 85: 780-781.
21. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M et al. Non myeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006; 12: 172-183.
22. Chang Y-J, Huang X-J. Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom? Blood Reviews 2013; 27: 55-62.
23. Porter David L, Alyea Edwin P, Antin Joseph H, DeLima Marcos, Eli Estey J. H, Falkenburg Frederik et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2010; 16: 1467-1503.
24. Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25: 4938-4945.